<DOC>
	<DOCNO>NCT01516307</DOCNO>
	<brief_summary>The purpose study compare active immunotherapy ( OPT-822/OPT-821 ) PBS combination low dose cyclophosphamide , post-treated metastatic breast cancer subject stable disease response treatment .</brief_summary>
	<brief_title>Trial Active Immunotherapy With Globo H-KLH ( OPT-822 ) Metastatic Breast Cancer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Female subject ≥ 21 year age histological cytological diagnosis breast carcinoma . Subjects metastatic breast cancer achieve stable disease ( SD ) , partial response ( PR ) , complete response ( CR ) least 1 regimen anticancer therapy ( i.e . chemotherapy target therapy , either alone combination ) . Involvement supraclavicular lymph node consider metastasis . Subjects must recover toxicity prior therapy . ( i.e . CTCAE ≤ grade 2 ) . Performance status : ECOG ≤ 1 life expectancy ≥ 3 month . Organ Function Requirements Subjects must adequate organ function define : AST/ALT ≤ 3X ULN ( upper limit normal ) AST/ALT ≤ 5X ULN [ underlie Liver Metastasis ] Total Bilirubin ≤ 2.0 X ULN Serum Creatinine ≤ 1.5X ULN ANC ≥ 1500 /μL Platelets &gt; 100,000/μL No Symptomatic Congestive Heart Failure ( Ejection Fraction EF ≥ 50 % ) Ability understand willingness sign write informed consent document accord institutional guideline . All positive negative ER ( estrogen receptor ) , PR ( progesterone receptor ) , HER2 subject eligible study . However , subject HER2 positive responsive antiHER2 therapy ( e.g . Herceptin ) , encourage remain antiHER2 therapy enroll trial . Subjects desire enroll study antiHER2 therapy available contraindicate , may eligible enroll trial . In country continuous antiHER2 therapy consider standard care HER2 positive metastatic disease , HER2 positive subject eligible . Women childbearing potential must willing implement adequate contraception study . An adequate method contraception investigator 's discretion . Subjects pregnant breastfeed entry . Subjects 2 event disease progression development metastatic breast cancer . Subjects currently receive concomitant anticancer therapy EXCEPTION bisphosphonates hormone therapy . During study period , subject use hormonal therapy bisphosphonates maintain constant dose change exist regimen . However , change hormonal therapy indicate , e.g . due intolerable adverse effect , regimen may modify change minimize thereafter . Subjects metastasis limit bone exclude . However , subject current metastasis limit bone history distant metastasis eligible . Subjects current metastasis limit bone current breast tissue lesion eligible . Subjects history malignancy ( except nonmelanoma skin carcinoma carcinomainsitu uterine cervix ) within 5 year study entry . Subjects splenectomy . Subjects HIV infection . Subjects major autoimmune disease autoimmune disorder require systemic iv/oral steroid immunosuppressive immunomodulatory therapy . e.g . Type 1 juvenile onset diabetes mellitus , antibody positive rheumatoid arthritis , Grave 's disease , Hashimoto 's thyroiditis , lupus , scleroderma , systemic vasculitis , hemolytic anemia , immune mediate thrombocytopenia , etc Autoimmune disorder confine skin ( e.g . psoriasis ) eligible , topical steroid allow treatment skin disorder . Subjects know uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Subjects follow MEDICATIONS within 4 week prior randomization : Antineoplastic agent Immunotherapy [ mAbs , Interferons , Cytokines ( except GCSF ) ] Immunosuppressants ( e.g . Cyclosporin , Rapamycin , Tacrolimus , Rituximab , Alemtuzumab , Natalizumab , etc. ) . Another investigational drug Subjects pleural effusion and/or ascites , due malignancy , require paracentesis every 2 week frequently . Subjects know severe allergy ( e.g . anaphylaxis ) active inactive ingredient study drug . Subjects bladder inflammation urinary outflow obstruction .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>